Drugs / CBL-A2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06005441 | Nov 2023 → Oct 2024 | panniculitis | Caliway Biopharmaceuticals Co., Ltd. | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBL-A2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06005441 ↗ |